This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Based in New Haven, CT, Alexion Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of life-transforming drugs, for the treatment of patients with ultra-rare disorders. The company’s complement franchise consists of key growth driver, Soliris, which is approved for the treatment of two severe and ultra-rare disorders resulting from chronic uncontrolled activation of the complement component of the immune system — paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Soliris is also approved for the treatment of generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody-positive. The FDA also approved its long-acting C5 complement inhibitor, Ultomiris, for the treatment of adult patients with PNH, to be administered every eight weeks. In October 2019, the FDA approved the use of Ultomiris as a treatment for adult and pediatric (one month of age or older) patients with aHUS to inhibit complement-mediated TMA.
IVERIC bio's (ISEE) Q2 Loss Narrows, Gene Therapy in Focus
by Zacks Equity Research
IVERIC bio (ISEE) second-quarter earnings improve year over year. The company is focusing on developing gene therapies for treating inherited retinal diseases.
Incyte (INCY) Q2 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Incyte (INCY) reports better-than-expected results for the second quarter of 2019, owing to strong Jakafi sales.
Alexion Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Alexion Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.
Alexion (ALXN) Q2 Earnings Beat Estimates, Guidance Raised
by Zacks Equity Research
Alexion (ALXN) beats both earnings and sales estimates in the second quarter of 2019 and raises 2019 guidance.
Alexion Pharmaceuticals (ALXN) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Alexion (ALXN) delivered earnings and revenue surprises of 11.86% and 2.49%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Is a Beat in the Cards for Celgene's (CELG) Q2 Earnings?
by Zacks Equity Research
Investors are looking forward to Revlimid's performance and updates on the acquisition by Bristol-Myers, when Celgene Corporation (CELG) reports Q2 results.
Is a Beat in Store for Repligen (RGEN) This Earnings Season?
by Zacks Equity Research
On Repligen's (RGEN) second-quarter earnings call, investor focus will be on its advancement with the proposed acquisition of C Technologies, Inc.
AMAG (AMAG) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
We expect AMAG (AMAG) to provide updates on its revenue-driving products, when it reports second-quarter earnings.
Buy 5 High-Flying Stocks Ahead of Q2 Earnings This Week
by Nalak Das
It will be prudent to invest in stocks that are likely to beat earnings estimates in the second quarter this week.
What's in Store for Anika Therapeutics' (ANIK) Q2 Earnings?
by Zacks Equity Research
On Anika Therapeutics' (ANIK) second-quarter earnings call, investor focus will be on its progress with the U.S. approval of its orthopedic product Cingal.
Alexion (ALXN) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Soliris' solid performance is likely to reflect in Alexion's (ALXN) second-quarter 2019 results.
Why Alexion (ALXN) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Alexion (ALXN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Is Alexion (ALXN) a Solid Growth Stock? 3 Reasons to Think " Yes "
by Zacks Equity Research
Alexion (ALXN) possesses solid growth attributes, which could help it handily outperform the market.
Alexion Pharmaceuticals (ALXN) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Alexion (ALXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ALXN or ALKS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ALXN vs. ALKS: Which Stock Is the Better Value Option?
Alexion (ALXN) Moves to Strong Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Alexion (ALXN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
6 Low Price-to-Book Value Stocks to Buy for Solid Returns
by Kinjel Shah
P/B ratio is emerging as a convenient tool for identifying low-priced stocks that have high growth prospects.
New Strong Buy Stocks for July 17th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
Alexion's Ultomiris Receives EU Approval for PNH in Adults
by Zacks Equity Research
Alexion (ALXN) obtains approval for its long-acting C5 complement inhibitor, Ultomiris, in Europe for PNH in adults.
Alexion Receives FDA Approval for Label Expansion of Soliris
by Zacks Equity Research
Alexion (ALXN) obtains FDA approval for Soliris for the treatment of neuromyelitis optica spectrum disorder.
Biotech Stock Roundup: Vertex, AMAG Drugs Get FDA Nod, Conatus Study Fails & More
by Zacks Equity Research
Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.
Alexion's sBLA for Ultomiris Gets Priority Review From FDA
by Zacks Equity Research
The FDA accepts Alexion's (ALXN) sBLA for Ultomiris under priority review for treating atypical hemolytic uremic syndrome to inhibit complement-mediated thrombotic microangiopathy. Shares increase.
3 Big Biotechs Hold Growth Potential in Second Half of 2019
by Ekta Bagri
We highlight a few leading players from the biotech sector, having surpassed the same so far in 2019 and are likely to put up a good show during the second half of 2019 as well.
The Zacks Analyst Blog Highlights: Amgen, Alexion, Regeneron, Allergan and Savara
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amgen, Alexion, Regeneron, Allergan and Savara
Alexion's (ALXN) Ultomiris Gets Approval in Japan for PNH
by Zacks Equity Research
Alexion (ALXN) receives approval in Japan for its long-acting C5 complement inhibitor, Ultomiris, for the PHN indication.